20 November at Pharmtech & Ingredients 2019
The round table discussion: API production: the economic aspect will take place on 20 November as part of Pharmtech & Ingredients 2019
Despite the decline in the supply of active pharmaceutical ingredients over recent years, financially, imports of APIs into Russia continue to grow.
One of the key objectives of the Pharma 2030 programme is to provide the pharmaceutical industry with enough in terms of stock and quantity locally produced raw materials, primarily pharmaceutical substances. But there are factors that hinder the production growth of locally produced substances, the main one being the need for large investments, high material intensity and energy intensity of substance production.
On the other hand, the resolution regulating public procurement of medicines, which came into force on 1 January 2019, introduced a new type of state support — a price preference of 25% of the minimum contract price. It will apply only to those companies that produce medicines in Russia and the EAEU countries on a full cycle, from the synthesis of the substance to packaging.
How can companies producing their own substances work according to the resolution and what economic benefits they can give? These and other issues will be discussed at the round table discussion API production: the economic aspect, on 20 November at Pharmtech & Ingredients.
Speakers will include representatives of regulatory bodies, leading industry experts, and representatives of API manufacturing companies.
Get your e-ticket to attend the event for free.